28 January, 2020
In the run up to World Cancer Day Fortress Diagnostics are proud to announce their commitment in collaborating with industry leaders in extensive research and manufacturing of a range of diagnostic tests.
Fortress Diagnostics invest 30% of annual turnover towards the research & development of custom tests including early cancer detection. The tests will assist clinicians to identify the presence of cancer on average four years before standard clinical diagnosis. Unlike the tumour antigens themselves, the levels of autoantibodies can be high even in the presence of an early stage tumour, due to the signal magnification created by the body’s immune response to a cancer. These autoantibodies can be measured easily on a simple enzyme-linked immunosorbent assay (ELISA) platform of which fortress diagnostics is making readily available in clinical laboratories around the world.
Our expert R&D team work collaboratively with many universities and research institutions including Queen’s University Belfast, the University of Cape Town and the University of Nottingham to develop custom tests, making new ideas a viable entity by utilising in-house resources at our UK-based ISO 13485:2016-accredited facility.
